At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 77 enrolled
Drug / intervention
CC-4047drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II, Prospective, Open-Label Study to Determine the Safety and Efficacy of CC-4047 in Patients With Primary, Post Polycythemia Vera, or Post Essential Thrombocythemia Myelofibrosis®
In Brief
A Phase 2 clinical trial evaluating CC-4047 for Chronic Myeloproliferative Disorders and Secondary Myelofibrosis. Completed, enrolled 77 participants across 1 site.
Detailed Summary
RATIONALE: Biological therapies, such as CC-4047, may stimulate the immune system in different ways and stop cancer cells from growing. CC-4047 may also stop the growth of cancer cells by blocking blood flow to the cancer. PURPOSE: This trial is studying the side effects and best dose of CC-4047 and to see how well it works in treating patients with myelofibrosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2008
Enrollment StartMay 2008
Primary CompletionJul 2010
Study CompletionDec 2019
TodayJul 2026
First PostedApr 30, 2008
Enrollment StartMay 1, 2008
Primary CompletionJul 7, 2010
Study CompletionDec 12, 2019
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 18.2 years ago
Interventions
CC-4047drug
CC-4047: taken orally each day in a 28 day cycle.